Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by forhandlarenon Apr 28, 2023 3:46pm
140 Views
Post# 35419938

RE:RE:RE:RE:What kills credibility

RE:RE:RE:RE:What kills credibility Biotech investments are risky business compared to other industries. Usually very small gains short term, but suddenly one day down to line the reward can be anywhere between 10 and 100 times the investment that balance the risk.

Anti-aging is the main compound here and the clinical results absolutely brilliant with room for improvement with another formulation. The risk has decreased significantly and now it's about spreading the word in the industry before the bidding process begin.

Seems like investors doesn't understand the magnitude here. Why people sell their shares for peanuts goes beyond my mind, probably the best investment opportunity in the industry now.

And no, the management will not give away this one for free. R+F was street cred and to some extent Abbvie as well. This is the real deal.
<< Previous
Bullboard Posts
Next >>